CJC-1295 and Ipamorelin Side Effects: Risks & Evidence

CJC-1295 and ipamorelin can cause reactions ranging from injection-site redness and flushing to anaphylaxis, a severe allergic reaction that can be fatal. Small human studies of each peptide reported mostly mild, short-lived effects, but no reliable data show how often reactions occur with the combination, and neither peptide is approved by the US Food and Drug Administration (FDA) as a drug for human use.

Key takeaways

• Reported effects: Small trials of CJC-1295 described transient injection-site redness and tenderness and a dose-dependent rise in heart rate; FDA also lists a systemic vasodilatory reaction.
• Most serious risk: A Victorian coroner found in October 2026 that a CJC-1295/ipamorelin injection triggered the anaphylaxis that led to actor Richard Norton's death.
• No frequency data: Case reports and regulator reports cannot tell you how common a reaction is.
• Single peptides are not the blend: Studies of each peptide alone cannot establish the safety of the combined product.
• Regulatory status: FDA lists safety concerns for both peptides, and neither is in the October 2026 HHS compounding policy.

Scope: This is a source explainer about reported side effects and safety evidence. It is not medical advice, a diagnosis or a dosing guide, and it has not been medically reviewed. PeptideStack is an informational and affiliate publisher, not a healthcare provider.

What are the side effects of CJC-1295 and ipamorelin?

Reported side effects of CJC-1295 and ipamorelin come from three different kinds of evidence: small clinical trials, regulator safety assessments and individual case reports. Each kind of evidence answers a different question, so the table below keeps them separate.

Effect or concern	Evidence source	What is known	Limitation
Injection-site redness and tenderness	CJC-1295 study in healthy men (Ionescu and Frohman, 2006)	Transient redness and tenderness at the injection site were among the most commonly observed effects.	A small group of healthy young men, single injection, one week of follow-up.
Increased heart rate	Same CJC-1295 study; FDA compounding safety list	The study described a dose-dependent, short-lived rise in heart rate. FDA lists increased heart rate among serious adverse events associated with CJC-1295.	No rate for people using the combination outside a trial.
Systemic vasodilatory reaction	FDA compounding safety list	FDA identifies it as a serious adverse event associated with CJC-1295.	FDA does not publish a frequency.
Immunogenicity and impurities	FDA compounding safety list	FDA says compounded products containing either peptide may pose immunogenicity risk and raise impurity and characterization concerns.	A regulatory risk assessment, not an observed reaction rate.
Anaphylaxis	Coroners Court of Victoria finding	The coroner found a CJC-1295/ipamorelin injection triggered anaphylaxis that led to cardiac arrest and death.	One case with other medical conditions; it does not establish how often anaphylaxis occurs.
Nerve, muscle or joint pain, swelling, carpal tunnel symptoms, numbness or tingling, headaches, higher glucose	Expert report quoted in the same coroner's finding	An independent medical expert listed these as likely adverse effects of CJC-1295/ipamorelin.	An expert opinion in a regulatory investigation, not trial data with a denominator.

None of these sources supports calling a reaction “common” or “rare” for people using CJC-1295 and ipamorelin together. The trials were small and short, and the case evidence has no denominator.

Can CJC-1295 and ipamorelin cause anaphylaxis?

Yes. A coroner found that a CJC-1295/ipamorelin injection caused a fatal anaphylactic reaction, and Australia's Therapeutic Goods Administration (TGA) has received three other reports of anaphylaxis in patients using that combination.

Anaphylaxis is a severe, whole-body allergic reaction that can develop within seconds or minutes. MedlinePlus lists warning signs that include:

• difficulty breathing, wheezing or chest tightness;
• swelling of the face, eyes or tongue, or difficulty swallowing;
• hives, itching or skin redness;
• dizziness, palpitations or loss of consciousness;
• nausea, vomiting or abdominal pain.

Emergency care: Anaphylaxis needs medical attention right away. MedlinePlus advises calling 911 in the United States or your local emergency number. Earlier, milder reactions are not a reason to keep injecting; a pattern of worsening reactions is a reason to stop and get medical advice.

What peptide was Richard Norton taking?

Richard Norton, the Australian martial artist and actor, was taking a prescribed CJC-1295/ipamorelin combination. On October 28, 2026, the Coroners Court of Victoria found that his death on March 30, 2025, was triggered by his injection of that peptide.

• Prescription: A medical practitioner prescribed the combination as experimental, off-label therapy and obtained it from a licensed compounding pharmacy in Queensland.
• Dosing: The finding records that Norton had been using more than the prescribed dose.
• Warning signs: Hospital records describe local redness and swelling after his first injection, then whole-body flushing over several days. On the morning of March 28, 2025, he had flushing, chest tightness and shortness of breath.
• Collapse: After a second injection that evening, he felt hot and flushed, then collapsed in cardiac arrest.
• Cause of death: Complications of an out-of-hospital cardiac arrest, due to anaphylaxis, with asthma and hypertrophic cardiomyopathy as contributing conditions.

The finding also records that the TGA has received six reports of anaphylaxis or hypersensitivity involving CJC-1295/ipamorelin, BPC-157 or thymosin beta-4, and TB-500. Three of those were anaphylaxis cases in patients using CJC-1295/ipamorelin, not counting Norton.

The coroner recommended that the TGA review peptides such as CJC-1295/ipamorelin and consider restricting them further, including possible classification under Schedule 10 of the Poisons Standard, the category for substances prohibited for supply and use.

What this case does not show

The finding concerns one person, the administered combination and his specific health history. It does not establish an anaphylaxis rate, and it does not show which of the two peptides, or which component of the product, caused the reaction. Post-mortem testing could not detect the specific peptides.

What have human clinical studies reported?

Published human trials studied CJC-1295 and ipamorelin separately, in small groups and for short periods. No published trial identified in this review tested the combined product for safety.

Study	Population	Intervention	Reported adverse events	What cannot be concluded
Teichman et al., 2006	Healthy adults aged 21 to 61	CJC-1295 under the skin in two randomized, placebo-controlled trials lasting 28 and 49 days	No serious adverse reactions reported; the authors described it as relatively well tolerated.	Long-term safety, safety in people with health conditions, or safety of the combination.
Ionescu and Frohman, 2006	Small group of healthy young men	One CJC-1295 injection, one week of follow-up	No serious adverse effects; transient injection-site redness and tenderness and a dose-dependent rise in heart rate.	Effects of repeated use or of combined products.
Beck et al., 2014	114 hospital patients after bowel surgery	Ipamorelin by intravenous infusion for up to seven days	Adverse events in 87.5% of the ipamorelin group and 94.8% of the placebo group; the authors called it well tolerated.	Safety of under-the-skin injection or long-term use; most events reflect recovery from surgery.

FDA's safety listing for ipamorelin acetate refers to a published study that “identified serious adverse events including death when ipamorelin was administered intravenously for improving gastric motility.” That finding concerns intravenous use in hospital patients and cannot be transferred directly to other routes or products. The FDA statement does not establish that ipamorelin caused the reported death or deaths, and it does not quantify the risk attributable to the drug.

What does the FDA say about their safety?

FDA lists both peptides on its page of bulk substances that may present significant safety risks in compounding, but in different sections.

• Ipamorelin acetate is in Category 2 under FDA's 503B interim policy. FDA cites potential immunogenicity from aggregation or peptide-related impurities, unnatural amino acids that complicate characterization, and the intravenous study above. It says it lacks safety information for some other injectable routes.
• CJC-1295 is listed among substances whose nominations were withdrawn. FDA cites immunogenicity risk for certain routes, impurity and characterization concerns, serious adverse events including increased heart rate and a systemic vasodilatory reaction, and limited clinical data.

In plain English, immunogenicity means the body's immune system may react to the product. Aggregation (peptide molecules clumping together) and impurities can increase that risk, and they are harder to control when a product's quality is uncertain.

The HHS peptide enforcement-discretion policy announced in October 2026 covers six other peptides and does not include CJC-1295 or ipamorelin. For approval, compounding and research-use status, see our CJC-1295 and ipamorelin FDA status guide.

Is ipamorelin safer than CJC-1295?

The available evidence does not establish that either peptide is safer than the other. The studies used different populations, routes and durations, so their results cannot be ranked against each other.

Ipamorelin's largest trial used intravenous infusion in surgical patients, while CJC-1295 was studied under the skin in healthy volunteers. Neither design tells you what happens when the two peptides are combined in one product and used repeatedly. For how the two compounds differ in mechanism, see CJC-1295 vs ipamorelin.

What remains unknown about long-term safety?

Long-term safety of CJC-1295 and ipamorelin is unknown. The main gaps in the evidence are:

• Reaction rates: No study measured how often side effects or allergic reactions occur in people using the combination.
• Combination data: No published safety trial of the combined product was identified.
• Duration: The human trials lasted days to weeks, not months or years.
• Immune response: How often the body reacts to these peptides, and to impurities in them, has not been measured.
• Product quality: Outside approved medicines, strength, purity and formulation can vary between products.
• Reporting gaps: Spontaneous reports to regulators undercount reactions and cannot provide a frequency.

Frequently asked questions

Is CJC-1295 and ipamorelin FDA approved?

No. Neither CJC-1295 nor ipamorelin is an FDA-approved drug, and FDA lists safety concerns for both in compounding. Our FDA status guide covers the details.

Are injection-site reactions a warning sign?

Local redness and tenderness were reported in a CJC-1295 study and often resolved quickly. In the Norton case, local redness and swelling were followed by whole-body flushing and breathing symptoms, so a reaction that spreads or worsens should be checked by a clinician, and breathing difficulty is an emergency.

Does the coroner's finding mean CJC-1295/ipamorelin is banned in Australia?

Not as of the finding. The coroner recommended that the TGA review these peptides and consider further restrictions; a recommendation is not itself a ban.

Sources and review limits

Sources checked November 3, 2026: the Coroners Court of Victoria finding into the death of Richard John Norton (COR 2025 001710, signed October 28, 2026), the FDA list of bulk drug substances that may present significant safety risks (content current as of April 22, 2026), the three PubMed study records linked above and the MedlinePlus anaphylaxis entry.

This explainer summarizes published evidence; it is not clinical verification of any product. PeptideStack may earn a commission from vendor links on this site, and those offers are separate from the safety information on this page.